Boxer Capital Management increased its Vir Biotechnology position by $9.89 million, reflecting a 100% stock surge over the past year.
Boxer Capital Management purchased 1.2 million shares of Vir Biotechnology (NASDAQ:VIR) on May 15, 2026, valued at $9.89 million based on quarterly average pricing. The transaction was disclosed in an SEC filing, lifting the fund’s stake in the biotech firm to 2.2% of its reportable assets under management as of March 31, 2026.
The fund’s Vir Biotechnology position grew by $12.95 million for the quarter, driven by both additional share purchases and a rise in the stock price. Vir Biotechnology shares closed at $9.09 on May 14, 2026, doubling over the past year and outperforming the S&P 500, which rose about 25% in the same period.
Boxer Capital’s top holdings include Tangent Pharmaceuticals (NASDAQ:TNGX) at $227.53 million, accounting for 29.9% of its AUM, followed by Kodiak Sciences (NASDAQ:KOD) and Revelation Biosciences (NASDAQ:RVMD). Vir Biotechnology focuses on infectious disease therapeutics, including COVID-19 and hepatitis B treatments.